ORRIN MAIN: Open Payments
NPI 1497367528 · ELIZABETH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,810 in 150 payments from 14 companies in 2025. Trend: 2023 $604 · 2024 $859 · 2025 $1,810
Food & beverage: $1,810
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $390 |
| E.R. Squibb & Sons, L.L.C. | 25 | $357 |
| Neurocrine BioSciences, Inc. | 43 | $303 |
| Otsuka America Pharmaceutical, Inc. | 16 | $172 |
| Axsome Therapeutics, Inc. | 15 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $86 |
| Neos Therapeutics, LP | 4 | $73 |
| Supernus Pharmaceuticals, Inc. | 5 | $71 |
| Janssen Pharmaceuticals, Inc | 3 | $54 |
| Alkermes, Inc. | 3 | $46 |
Products named: VRAYLAR, COBENFY, INGREZZA, REXULTI, Auvelity, CAPLYTA, Sunosi, Qelbree.
Industry payments across NJ — which companies pay providers there.
